Drug–drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation
Authors:
- Dmitry SychevDSDmitry Sychev
- Karin MirzaevKMKarin Mirzaev
- Marina CherniaevaMCMarina Cherniaeva
- Maria KulikovaMKMaria Kulikova
- Pavel BochkovPBPavel Bochkov
- Roman ShevchenkoRSRoman Shevchenko
- Olga GolovinaOGOlga Golovina
- Olga OstroumovaOOOlga Ostroumova
- Damirya BahteevaDBDamirya Bahteeva
- Eric RytkinEREric Rytkin
- 1 September 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 35 (3)
Abstract
Objectives: For revealing the peculiarities of the drug–drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil – inhibitor CYP3A4 and P-gp and amlodipine – substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients. Methods: All patients were divided into groups depending on the therapy taken: the 1st – rivaroxaban + amlodipine (n=51), the 2nd – rivaroxaban + verapamil (n=30), the control group – rivaroxaban without CCBs (n=47). A trough steady-state plasma concentration (C min,ss) of rivaroxaban, prothrombin time (PT) in the blood plasma and the event of clinically relevant non-major (CRNM) bleeding were assessed for each patient. Results: Patient in group 2 had higher C min,ss of rivaroxaban, PT and CRNM than subjects in the control group (Me 73.8 [50.6–108.8] ng/mL vs. 40.5 [25.6–74.3] ng/mL; Me 14.8 [13.4–17.3] s vs. 13.8 [12.6–14.4] s; 34% vs. 13%, respectively, p0.05 for all). Conclusions: In patients ≥80 years with NAF, the use of rivaroxaban in combination with verapamil may not be safe and can lead to CRNM bleeding.Keywords
This publication has 31 references indexed in Scilit:
- Detection of Atrial Fibrillation After Ischemic Stroke or Transient Ischemic AttackStroke, 2014
- Amlodipine Metabolism in Human Liver Microsomes and Roles of CYP3A4/5 in the Dihydropyridine DehydrogenationDrug Metabolism and Disposition, 2014
- Improved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic StrokeStroke, 2013
- Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult PopulationThe American Journal of Cardiology, 2013
- The P-Glycoprotein Transport System and Cardiovascular DrugsJACC, 2013
- Comparison of Cardiovascular Risk Factors and Survival in Patients with Ischemic or Hemorrhagic StrokeInternational Journal of Stroke, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior DistributionsJournal of the American Statistical Association, 1996
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991